Navigation Links
Case Management Cost-Effective Way to Cut Heart Risks
Date:8/29/2007

California study shows such visits with patients reduced risk by 10% and also cut costs

WEDNESDAY, Aug. 29 (HealthDay News) -- Case management provided a cost-effective way of reducing patients' overall risk of heart disease by about 10 percent, according to a study by researchers at Stanford University in California.

In case management, specially trained health professionals such as nurses and dietitians help patients manage chronic conditions on a long-term basis. Case managers handle many of the patient counseling and tracking roles normally done by doctors.

"Case management makes a lot of sense when it comes to chronic disease, because you need to have constant contact with patients to pick up on any problems before they get worse," study lead author Dr. Randall Stafford, an associate professor of medicine at the Stanford Prevention Research Center, said in a prepared statement.

This 17-month study included 341 patients randomly assigned to receive either primary care alone or primary care augmented by case management visits. Patients in the case management group had an average of 14 hours of contact with their case manager during the study.

During visits that lasted 40 minutes to 60 minutes each, patients and case managers reviewed the patient's progress on lifestyle and medication goals and developed a plan for the next few weeks.

At the start of the study, all the participants had a 10 percent to 15 percent risk of suffering a heart attack or severe heart disease over the next 10 years. After the study, the researchers estimated that patients in the case management group had lowered their risk by about 1.6 percent -- about a 10 percent reduction.

The overall cost of the case management visits was about $1,250 per patient, which is about the same as six regular office visits to a primary care doctor. That's a small amount to reduce the risk of a heart attack, which can result in more tha
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. New Modality in Migraine Management
2. Self-Management Program Beneficial for Back Pain
3. Self-Management Program Beneficial for Back Pain
4. Disease Management Programs – Effective for Heart Patient
5. Effective Management Of Heart Patients
6. New advance in prostate cancer management
7. Gastrin, Much More Than The Weight Management Hormone
8. Medical Management Now Available For Miscarriage
9. Early Awareness About Weight Management Needed To Tackle Lifelong Obesity
10. Exercise For Effective Pain Management In Old People
11. Glimepiride in the medical management of Type 2 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)... Dr. Stephen Cohen Hired As New CEO, ATLANTA,...r Group,(GMCG) announced today that MELCO Investme...ment fund, has signed on as a key partner with a,s...the investment, GMCG has,also appointed Dr. Stephe...,surgeons, as its new CEO., (Photo: http://www.n...
(Date:7/23/2008)...d and Medicare Rules Highlighted; a Focus on Preve...tions, LANSING, Mich., July 23 /PRNewswire/ -- Th...&PSI), a national leader in clinical risk manageme... care institutions and,providers, today announced ... conference., The conference will take place Sept...
(Date:7/23/2008)... Michigan Takes Top Honors as the #1 Healthiest Ci...PRNewswire-USNewswire/ -- AARP The Magazine, the,d...largest-circulation,magazine with more than 34 mil...st cities to live and retire in with Ann Arbor, MI...go, ND taking the top five rankings.,Featured in t...
(Date:7/23/2008)...a., July 23 /PRNewswire-USNewswire/ -- The HealthC...m ) today announced that Dr. Fran Cogen,MD, direc...am at Children,s,National Medical Center, will pro...om, a site offering connections to a community of ...priate consultation by a dietician, social,worker,...
Breaking Medicine News(10 mins):Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 2Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 3Health News:The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 3Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 4Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 5Health News:Children's National Medical Center Program Director to Provide Expertise to DiabeTeens.com, The HealthCentral Network's Teen Diabetes Site 2
...nza can be slowed by immunizing chickens. The dise...vaccine has been developed for protecting chickens...ndrea Gambotto of the University of Pittsburgh. ... advantageous way of stopping the spread of the di...
...ter of the Indian state of Kerala underwent a surg...ng his hip after a fall. // He was visiting Switze..., with the object of promoting his state as an inv...overing well after the surgery, even though he wil...
...ission (NHRC) has called for a report with regard ...dneys and has issued the Chief Secretary and the D...unjab with a notice. // As many as 300 laborers i...eys since the year 2001, and about 25 of them are ...
...e US in 2005 from the fatal arrhythmias through de...As many as 1,70,000 people in North America receiv...o found this to be uncomfortable, unnecessary, and...loped recently to find out which of the patients a...
Other Medicine News:
(Date:7/22/2008)...r Therapeutics Development Initiative bring MJFF,s...t deadline January 20,2009, NEW YORK, July 22 /P...,speed delivery of transformative treatments and a...Foundation for Parkinson,s Research has awarded,$2...ch teams. The awards,were granted under MJFF,s The...
(Date:7/22/2008)...T Study Confirms Tyrima Exhibits Excellent Drug-Li... - Results Support Initiation of Phase II Clinical.../- CeNeRx BioPharma,Inc., a clinical...vative,treatments for diseases of the central nerv...ead candidate Tyrima(TM) into Phase II trials for ...
(Date:7/22/2008)...O, Calif., July 22 /- Hyperion,Therap... patient enrollment,in its Phase 1/2 clinical tria... scavenging effects of HPN-100 (formally called GT...patients with urea cycle disorders,(UCD). The comp...th quarter,of this year., (Logo: http://www.news...
(Date:7/22/2008)...novative Laser Lipolysis Technology in the Europea..., Mass., July 22 /- Cynosur...manufacturer of a broad array of,light-based aesth...CE Mark,for Smartlipo MPX(TM), the company,s high-...liquefy fat and tighten skin through collagen,remo...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation 2Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation 3Living longer with obesity means heavier burden for hospitals 7969 1Living longer with obesity means heavier burden for hospitals 7969 2Living longer with obesity means heavier burden for hospitals 7969 3Mutated Suppressor Gene Leads to a Type of Breast Cancer 7967 1Mutated Suppressor Gene Leads to a Type of Breast Cancer 7967 2Mutated Suppressor Gene Leads to a Type of Breast Cancer 7967 3New drug candidate knocks out resistant form of chronic myeloid leukemia 7964 1New drug candidate knocks out resistant form of chronic myeloid leukemia 7964 2Decreasing access to cigarettes for youth in the Minnesota Adolescent Community Cohort Study 7961 1
... - Abraxis BioScience,Inc. (NASDAQ:ABBI), an inte...d first-time data from a pre-clinical study,evalua...mycin,(ABI-009), an albumin-bound mTOR kinase inhi... Research (AACR) Annual Meeting held,April 14-18, ...,study demonstrated that nab-rapamycin was well-to...
...r 19, 2007 - Amgen,(NASDAQ: AMGN) today announced ...le-blind, placebo-controlled, multicenter Phase 3,...iously untreated,patients with extensive-stage sma...aining chemotherapy. The study demonstrated,no sta... (overall,survival Aranesp compared to placebo Haz...
Other Medicine Technology:Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 2Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 3Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 4Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 2Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 3Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 4Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 5Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 6Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 7
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor
Centuries of German Craftsmanship have produced the finest surgical instrumentation in the world. Ocutek® now makes them available to you! Only holders of the coveted Meisterbrief certificate, wh
Centuries of German Craftsmanship have produced the finest surgical instrumentation in the world. Ocutek now makes them available to you! Only holders of the coveted Meisterbrief certificate, which r
Centuries of German Craftsmanship have produced the finest surgical instrumentation in the world. Ocutek now makes them available to you! Only holders of the coveted Meisterbrief certificate, which r
Medicine Products: